FOLH1 and Familial prostate cancer: Currently, prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is increasingly employed for staging of patients with intermediate- and high-risk primary prostate cancer, as well as in patients experiencing recurrence after treatment with curative intent [1, 2].